http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
This book focuses on the importance of regulatory RNAs in the vasculature. The main topics discussed include the role of regRNAs in vascular development and angiogenesis, ischemic cardiovascular disease and repair mechanisms, diabetic and metabolic vascular disease, atherosclerosis and vascular inflammation, as well as diagnostics of vascular disease using circulating miRNAs. Lastly, it offers an overview of emerging topics such as microvesicle-mediated miRNA cellular trafficking and the vascular importance of long non-coding RNAs. It is an invaluable resource for academics, researchers and students working in the field of vascular biology.
Preface; Contents; 1: Regulation of Atherosclerosis by microRNAs; 1.1 Introduction; 1.2 miRNA-Mediated Regulatory Mechanisms; 1.2.1 Regulatory Mechanisms of miRNA Strands Derived from a Single Precursor; 1.2.2 RNA Sponges in the Regulation of miRNA Activity; 1.2.3 Circulating miRNAs: Messengers on the Move; 1.3 Regulation of Inflammatory Macrophage Activation by a miRNA Tandem; 1.4 Combined Roles of miR-126-3p and miR-126-5p in Endothelial Regeneration and Their Use in Therapeutic Approaches; 1.5 Lipoprotein-Mediated miRNA Transfer; 1.6 Conclusions and Future Work; References.
2: Noncoding RNAs in Cholesterol Metabolism and Atherosclerosis2.1 Introduction; 2.2 miRNAs Regulating HDL-C Metabolism and Reverse Cholesterol Transport; 2.2.1 miR-33a/miR-33b; 2.2.2 miR-33a/miR-33b and Atherosclerosis; 2.3 miRNAs and LDL-C Metabolism; 2.3.1 miRNAs That Regulate Cholesterol Biosynthesis and VLDL Secretion; 2.3.1.1 miR-122; 2.3.1.2 miR-30c in Lipid Metabolism and Atherosclerosis; 2.3.1.3 miR-33a/miR-33b; 2.3.1.4 miR-96/miR-182/miR-183; 2.3.2 miRNAs That Regulate LDLR Expression and LDL-C Clearance; 2.3.2.1 miR-148a; 2.3.2.2 miR-128-1; 2.3.2.3 miR-185.
2.4 LncRNAs and Cholesterol Metabolism2.4.1 LeXis; 2.4.2 Lnc-HC and ApoA1-AS; 2.4.3 LncLSTR; 2.5 Concluding Remarks; References; 3: MicroRNAs in Diabetes and Its Vascular Complications; 3.1 Introduction; 3.2 MicroRNAs in Diabetes Mellitus; 3.2.1 Pancreas; 3.2.2 Adipose Tissue; 3.2.3 Muscle; 3.2.4 Liver; 3.3 MicroRNAs Modulating the Impact of Diabetes Mellitus on Bone Marrow and on Stem and Progenitor Cells; 3.4 MicroRNAs in Diabetic Cardiovascular Complications; 3.4.1 Microvascular Complications; 3.4.1.1 Nephropathy; 3.4.1.2 Retinopathy; 3.4.1.3 Neuropathy.
3.4.2 Cardiac Disease3.4.3 Peripheral Vascular Disease; 3.5 MicroRNA as Circulating Biomarkers of Diabetic Cardiovascular Disease; 3.6 Concluding Remarks; References; 4: Noncoding RNAs in Ischemic Cardiovascular Disease and Repair Mechanisms; 4.1 Targeting miRNAs to Enhance Cell-Based Therapies; 4.2 Targeting miRNAs to Induce a Cardiac Phenotype in Pluripotent Stem Cells; 4.3 Targeting miRNAs to Facilitate Cardiac Regenerative Pathways; 4.4 MiRNAs in the Development and Progression of Heart Failure; 4.5 Long Noncoding RNAs in Cardiovascular Disease; References.
5: Circulating microRNAs as Novel Biomarkers in Cardiovascular Disease: Basic and Technical Principles5.1 Introduction; 5.2 MicroRNA Biogenesis and Function; 5.3 Circulating miRNAs; 5.3.1 miRNAs in Vesicles; 5.3.1.1 Apoptotic Bodies; 5.3.1.2 Microparticles; 5.3.1.3 Exosomes; 5.3.2 miRNAs in Protein Complexes; 5.3.3 miRNAs in Lipoprotein Complexes; 5.4 Quantification of Circulating miRNAs; 5.4.1 Sample Preparation; 5.4.1.1 Sample Processing and Handling; 5.4.1.2 RNA Isolation; 5.4.2 Data Normalisation; 5.4.3 Comprehensive Profiling of Circulating miRNAs.
Thomas Thum, Stefanie Dimmeler, editors.
Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty